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        The genus   Orthopoxvirus   (OPV) comprises a 
large number of morphologically identical vi-
ruses, including the agent of human smallpox 
variola virus (VARV), the agent of mousepox 
ectromelia virus (ECTV), the vaccine species 
vaccinia virus (VACV), and monkeypox virus, 
a zoonotic virus with its natural reservoir in 
African rodents. 
  Smallpox, a grave systemic disease charac-
terized by high mortality and responsible for 
the death of billions over at least three millen-
nia (  1  ), was eradicated worldwide in the late 
1970s through vaccination with VACV. How-
ever, there is fear that VARV could be used as 
a weapon. This would be devastating, because 
massive vaccination against smallpox was dis-
continued in 1978 and most of the human 
population is presently not immune. In addi-
tion, the reduced level of herd immunity against 
OPV increases the possibility of infection with 
zoonotic monkeypox virus, as exemplifi  ed by 
its current endemic status in central and west 
Africa, as well as a recent outbreak in the US 
Midwest (  2  –  4  ). Moreover, because there are 
many other OPVs in nature, there is a threat of 
emerging OPV zoonoses. 
  The current smallpox vaccine uses live 
VACV, which is normally poorly or nonpatho-
genic to humans but induces cross-protective 
immunity against other OPVs. However, be-
cause of cases of adverse eff  ects, including gen-
eralized infection and death, the live VACV 
vaccine is not safe by current standards (  1, 5, 6  ). 
On the other hand, killed VACV induces anti-
bodies but is not eff  ective at preventing disease, 
perhaps because it does not induce a subset of 
antibodies important for protection (  7  –  12  ). 
Therefore, there is a need to replace the current 
VACV-based vaccine (Dryvax) with a safer 
vaccine that, ideally, should be noninfectious, 
such as subunit vaccines based on recombinant 
(Rec) viral proteins or DNA. However, it will 
be diffi   cult to evaluate the effi   cacy of new vac-
cines in the absence of human smallpox or 
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  Nonliving antiviral vaccines traditionally target proteins expressed at the surface of the 
virion with the hope of inducing neutralizing antibodies. Orthopoxviruses (OPVs), such as 
the human smallpox virus and the mouse-equivalent ectromelia virus (ECTV; an agent of 
mousepox), encode immune response modifi  ers (IRMs) that can increase virulence by 
decreasing the host immune response. We show that one of these IRMs, the type I inter-
feron (IFN) binding protein (bp) of ECTV, is essential for ECTV virulence and is a natural 
target of the antibody response. More strikingly, we demonstrate that immunization with 
recombinant type I IFN bp protects mice from lethal mousepox. Collectively, our experi-
ments have important implications for our understanding of the role of IRMs in OPV 
virulence and of type I IFNs in OPV infections. Furthermore, our work provides proof of 
concept that effective antiviral vaccines can be made to prevent disease by targeting 
virulence factors as an alternative to the traditional approach that attempts to prevent 
infection by virus neutralization. 982 ECTROMELIA VIRUS TYPE I IFN BINDING PROTEIN IN VIRULENCE AND AS A VACCINE | Xu et al.
(EVM166) and is 88% identical with both the VACV and the 
VARV orthologues (  13  ). However, whether the ECTV pro-
tein binds mouse IFN with similar or diff  erent affi   nity than 
the VACV protein is not known. 
  The role of IFN bp in OPV virulence is still not com-
pletely clear. For example, VACV defi  cient in the IFN-     bp 
was not attenuated in mice (  48  ). However, this is not signifi  -
cant because VACV IFN-     bp does not inhibit the biological 
activity of mouse IFN-     (  49  ). On the other hand, deletion of 
the IFN-     bp results in moderate attenuation of ECTV (  50  ). 
In the case of the type I IFN bp, its deletion in VACV (B19R, 
formerly B18R) results in     100-fold attenuation of VACV 
in mice challenged through the intranasal route. However, 
whether the type I IFN bp plays any role in ECTV virulence 
has not been determined. A comparative analysis is of partic-
ular interest given the fact that ECTV is much more patho-
genic for the mouse than VACV. 
  Vaccines provide immunity by mimicking some aspects 
of the natural infection. Immunity to OPV in humans and 
mice is characterized by the presence of circulating antiviral 
antibodies and relatively high frequencies of memory T and 
B lymphocytes specifi  c for the virus (  51  –  55  ). Experiments of 
passive immunization showed that either preexisting anti-
body or memory CD8  +   T cells can protect immunocompe-
tent mice from mousepox ( 28, 56 ) However, neither antibody 
nor memory CD8  +   T cells transfer reduced virus replication 
at the site of entry or completely abrogated systemic virus 
spread (  56  ). These fi  ndings are not opposed to the concept of 
protective immunity. Indeed, it is well established that VACV 
immunization does not completely prevent ECTV or VACV 
replication or spread in mice or in humans, respectively (  28, 
56  ). Therefore, although vaccines should ideally prevent in-
fection, the fact that immunization with VACV does not 
prevent virus replication but was very eff  ective at eradicating 
smallpox indicates that protective humoral immunity may 
use antibodies that do not neutralize the viral particles but 
that target secreted virulence factors. In this study, we dem-
onstrate that the type I IFN bp is essential for ECTV viru-
lence, a natural target of the antibody response, and constitutes 
an eff  ective target for protective immunization. 
    RESULTS   
  The type I IFN bp is essential for ECTV virulence 
  To elucidate the importance of the type I IFN bp in ECTV 
virulence, we made ECTV with EVM166 deleted (    166), 
where EVM166 was replaced with enhanced GFP (EGFP; 
Fig. S1 A, available at http://www.jem.org/cgi/content/
full/jem.20071854/DC1) (  26  ). In addition, as a control for 
any defects that     166 may have acquired in other loci during 
cloning, we also generated a revertant virus (    166 revertant 
to WT [Rev166]) in which EVM166 was reintroduced to its 
original location in     166 (Fig. S1 B). Correct replacement/
reinsertion of EVM166 in     166 and Rev166 was confi  rmed 
by amplifi  cation and sequencing of DNA fragments using 
primers lying outside of the homologous recombined sequences 
(unpublished data). 
information regarding the correlates of immunity. Thus, the 
design and testing of new types of smallpox vaccines will be 
facilitated by advances in our understanding of the viral patho-
genesis and immunology to lethal poxvirus infections. 
  OPVs and other poxviruses such as the   Leporipoxvirus   
myxoma virus (the agent of myxomatosis in the European 
rabbit) encode nonstructural proteins that play important roles 
in host specifi  city and virulence (  13  –  21  ). Some of these pro-
teins are secreted immune response modifi  ers (IRMs) that may 
or may not bind to the surface of cells. These secreted IRMs 
can either mimic (virokines) or compete (viroreceptors) 
with the function of chemokines, cytokines, and growth factors 
(  22  –  24  ). Although we still lack a complete understanding of 
the role of IRMs in poxvirus pathogenesis, it is clear that 
some play an important role in the virulence of myxoma virus 
in rabbits and of VACV when inoculated intranasally to mice 
(  25, 26  ), Because secreted IRMs are exposed to the extracel-
lular milieu, it is very possible that they are targets of the host  ’  s 
antibody response. However, this has not been formally 
tested. Furthermore, antibodies to secreted IRMs important 
for virulence could be signifi  cant for protective immunity and 
be used as targets of novel vaccine strategies. 
  The OPV ECTV has host specifi  city for the mouse and, 
in susceptible strains such as BALB/c mice, produces sys-
temic lethal mousepox when inoculated with as little as     1 
PFU through the footpad and other routes (  24  ). Moreover, 
mousepox is remarkably similar to human smallpox and can 
also be prevented by VACV inoculation (  27, 28  ). Of interest, 
most of the IRMs in VARV are also present in ECTV. Con-
sequently, it is very likely that they play similar roles in patho-
genesis in their respective natural hosts. Thus, ECTV is an 
excellent model to understand the role of IRMs in pathogen-
esis and as possible candidates for new anti-OPV vaccines. 
  IFNs are proinfl  ammatory cytokines produced in high 
quantities and during the early stages of viral infections. By 
inducing an antiviral state in cells (  29  ) and modulating the 
immune response (  30  ), IFNs are major mediators of the anti-
viral defense (  31  ). Type I IFN-     and -     use a common het-
erodimeric receptor (IFN-    /    R), composed of IFNAR1 and 
IFNAR2, that is ubiquitously expressed (  32  ). Type I IFNs 
can be produced by almost any infected cell, but in some viral 
infections are mostly produced by plasmacytoid dendritic 
cells (  33  –  35  ). The type II IFN-     is mainly the product of NK 
cells and CD8  +   and CD4  +   T cells, and binds to IFN-    R at 
the surface of cells. 
  IFNs play an important role in resistance to OPV infec-
tions. Mice defi  cient in type I and II IFNR or IFN-     are 
highly susceptible to VACV infection (  36  –  39  ). Similarly, type I 
and II IFNs are essential for natural resistance to mousepox in 
129 and C57BL/6 (B6) mice, as demonstrated in experiments 
of antibody depletion, or with mice defi  cient in IFN-    , IFN 
    /    R, or IFN-    R (  40  –  43  ). 
  OPVs encode IRMs that are type I and II IFN binding 
proteins (bp  ’  s) that compete with type I or II IFNR for their 
ligands, respectively (  13, 44  –  47  ). In ECTV, the type I IFN 
bp is encoded by ECTV Moscow open reading frame no. 166 JEM VOL. 205, April 14, 2008 
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ingly, all of the mice infected with ECTV     166 survived, 
whereas all of those infected with Rev166, 189898-p7.5-
EGFP, or WT ECTV died (  Fig. 2 C  ). Moreover, none of 
the BALB/c mice infected with     166 demonstrated overt 
symptoms of mousepox or major weight loss (unpublished 
data). In additional experiments, we found that the dose of 
ECTV WT, Rev166, or 189898-p7.5-EGFP that killed 
50% of BALB/c mice was   <  5 PFU. On the other hand, no 
deaths were observed in BALB/c mice infected with up to 
5   ×   10  7   PFU     166, the maximum dose that our virus stock 
permitted (  Table I  ).   Thus, from these experiments we con-
clude that     166 is attenuated at least 10  7  -fold. Because the 
LD  50  s of Rev166, 189898-p7.5-EGFP, and WT ECTV were 
comparable, we also conclude that the avirulence of     166 is 
caused by the absence of the type I IFN bp and not other 
factors such as expression of EGFP. Collectively, these re-
sults demonstrate that the type I IFN bp is essential for 
ECTV virulence. 
  Although the data presented in this section demonstrate 
that ECTV is avirulent without the type I IFN bp, it is possi-
ble that an unknown function of the type I IFN bp (other 
than type I IFN blockade) was responsible for the phenotype. 
Similar to B6 mice, 129/Sv mice are naturally resistant to 
mousepox after infection with WT ECTV. However, 129 
mice defi  cient in IFNAR1 (a component of the IFN-    /    R) 
  We next characterized the viruses for their ability to repli-
cate and block the biological function of IFN-     in tissue cul-
ture. We found that ECTV    166, Rev166, and WT produced 
similar amounts of infectious virus in multistep growth curves, 
as determined in mouse A9 cells (  Fig. 1 A  ), as well as in mon-
key BSC-1 cells (not depicted).   This indicates that the type I 
IFN bp is not required for ECTV replication in tissue culture 
and is consistent with expectations for a nonstructural secreted 
protein that does not play a role in DNA replication or virus 
assembly. In addition, supernatants from cells infected with 
Rev166 but not from     166 were able to block the biological 
function of IFN-    , as determined in vesicular stomatitis virus 
(VSV) IFN protection assays (  Fig. 1 B  ). This provides a func-
tional confi  rmation of the correct deletion/reinsertion of 
EVM166 in     166 and Rev166, respectively, and indicates 
that other than EVM166, ECTV does not encode any secreted 
protein capable of blocking the function of IFN-    . 
  The natural route of ECTV entry is through microabra-
sions of the footpad (  57  ). Via this route, it fi  rst multiplies at 
the site of entry followed by spread to and replication in the 
local draining lymph node (D-LN). From there, ECTV fol-
lows the eff  erent lymphatic vessels to reach the blood and 
then visceral organs, such as the liver and the spleen (  57  ). In 
mousepox-susceptible BALB/c mice, the massive replication 
of ECTV in the liver results in acute liver necrosis and death 
within 8  –  11 d post infection (PI). Any BALB/c mouse that 
survives this phase develops a typical skin exanthema and ex-
periences weight loss of 25  –  30% of its initial body weight 
(  28, 56, 58  ). To determine whether the type I IFN bp is im-
portant for effi   cient ECTV replication and spread in vivo, we 
infected BALB/c mice in the footpad with 300 PFU of 
ECTV     166, Rev166, or WT. 3, 5, and 7 d PI, we quanti-
fi  ed virus loads in the infected footpad to determine local 
replication, and the spleen and liver to determine spread (  Fig. 
2 A  ).   The results showed that the type I IFN bp is not very 
important for ECTV replication at the initial site of infec-
tion, because at every time PI, only minor diff  erences in virus 
loads of the three viruses were found in the infected foot-
pads. However, the virus loads of     166 were     10  4  - and     10  3  -
fold lower in spleen and liver, respectively, than those of WT 
or Rev166, indicating that the type I IFN bp is required for 
the effi   cient spread of ECTV to visceral organs. Consistent 
with these results, infection with     166 resulted in decreased 
anatomical pathology in organs. Macroscopic observation 
showed that, as expected, the D-LNs (left popliteal) and 
spleens of mice infected with WT ECTV were reduced in 
size compared with naive mice, and their spleens and livers 
were necrotic. Conversely, the D-LNs and spleens of mice 
infected with     166 were enlarged, and their livers had a 
normal appearance (  Fig. 2 B  ). 
  To further determine the role of the type I IFN bp in 
ECTV virulence, we infected BALB/c mice with 300 PFU 
of ECTV     166, Rev166, or WT and determined survival. 
As an additional control, we also infected a group of mice 
with ECTV 189898-p7.5-EGFP, which has EGFP inserted 
in a noncoding region of the ECTV genome (  59  ). Strik-
    Figure 1.         In vitro characterization of     166 and Rev166 ECTV.  
(A) Mouse fi  brosarcoma A9 cells were infected with 0.01 PFU/cell of the indi-
cated viruses. Cell-associated and free virus were determined at the indi-
cated times after infection. Data points are means   ±   SD of three replicate 
wells. (B) Confl  uent L929 cells in 24-well plates were treated with 200   μ  l 
of supernatants from BSC-1 cells infected as indicated. After 1 h of incu-
bation, 300   μ  l of media with or without 50 IU IFN-     was added. The cells 
were incubated for an additional 24 h, followed by infection with 10 PFU/
cell VSV. After 24 h of incubation, the cells were washed, fi  xed, and stained 
with crystal violet.     984 ECTROMELIA VIRUS TYPE I IFN BINDING PROTEIN IN VIRULENCE AND AS A VACCINE | Xu et al.
mice mounted a very strong CD8  +   T cell response to     166 
in the popliteal D-LN but, as expected (  56, 64  ), not to 
Rev166 (  Fig. 3 A  ).   A similar observation was made for the 
CD4  +   T cell response (unpublished data). In addition, we 
also found an increase in the D-LN T cell response to     166 
as compared with Rev166 in mousepox-resistant B6 mice 
(unpublished data). We next tested whether the type I IFN 
bp may also aff  ect innate immunity. When RAG-1  –  defi  cient 
mice (which lack adaptive immunity) were infected with 
    166, they died from mousepox, but several days later than 
mice infected with Rev166 (  Fig. 3 B  ), indicating that in ad-
dition to adaptive immunity, the type I IFN bp aff  ects innate 
immunity. We reasoned that NK cells might be one compo-
nent of innate immunity aff  ected by the type I IFN bp be-
cause we and others have shown that NK cells are essential 
rapidly die from WT ECTV infection (  43  ). Importantly, we 
found that     166 regained virulence in IFNAR1-defi  cient 
129/Sv mice (  Fig. 2 D  ). This result strongly suggests that 
    166 ECTV is avirulent in BALB/c mice because it is unable 
to block the antiviral eff  ects of type I IFN. 
  The type I IFN bp decreases anti-ECTV innate 
and adaptive immunity 
  We and others have shown that T cells are essential for the 
natural resistance of B6 mice to mousepox (  55, 60  –  62  ) and 
that a very strong T cell response can be detected in the 
D-LN of B6 mice 5 d PI (  63  ). We have also recently shown 
that, diff  erent from B6 mice, the T cell response to WT 
ECTV in the D-LN of mousepox-susceptible naive BALB/c 
mice is almost undetectable (  56  ). Interestingly, naive BALB/c 
    Figure 2.         ECTV     166 is avirulent in immunocompetent mice but virulent in IFNAR1-defi  cient mice.   (A) BALB/c mice were infected with 300 
PFU of the indicated viruses. Virus titers in the infected footpad and spleen were determined at the indicated times. Data points are means   ±   SD of three 
mice. (B) BALB/c mice were infected with the indicated viruses, and organs were harvested and photographed 7 d PI. (C) BALB/c mice were infected in the 
footpad with 300 PFU of the indicated viruses and observed for survival. Data correspond to fi  ve mice per group. (D) IFNAR1-defi  cient or control 129S2/
SvPasCrl mice were infected with 300 PFU of the indicated viruses and observed for survival. Data correspond to fi  ve mice per group.     JEM VOL. 205, April 14, 2008 
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type I IFN bp is not required for eff  ective binding to mouse 
IFN-    . All subsequent experiments in the study were thus 
performed with the protein expressed in   E. coli  , which is eas-
ier and less expensive to generate in large quantities than the 
protein produced in the baculovirus system. Of interest, we 
also found that Rec type I IFN bp inactivated the biological 
activity of IFN-     in VSV IFN protection assays (  Fig. 4 B  , 
left). However, it did not block the biological activity of 
mouse IFN-     (  Fig. 4 B  , right), which is consistent with a 
previous study (  44  ). Interestingly, when BALB/c mice were 
infected with     166 and also inoculated with Rec type I IFN 
bp, they died from mousepox (  Fig. 4 C  ), but not when inoc-
ulated with Rec type I IFN bp alone. This demonstrated that, 
in addition to binding and blocking the biological function of 
IFN-     in vitro, the Rec type I IFN bp can complement the 
defect of     166 in vivo. 
  The type I IFN bp is a natural target of the anti-OPV 
antibody response 
  Infection with OPVs are well known to induce a strong anti-
body response against multiple structural components of the 
virions (  55, 64, 67, 68  ). Consistent with this, antisera to 
ECTV WT,     166, or Rev166 contained antibodies that rec-
ognized purifi  ed ECTV virions ( Fig. 5 A ).   However, whether 
secreted IRMs can also be targets of the antibody response is 
not known. This question is important because antibodies 
for resistance to mousepox (  59, 62, 65  ). In addition, recent 
publications from our laboratory and from Parker et al. (  59, 
65  ) showed that on day 2 PI, ECTV recruits NK cells to the 
D-LN. We found that the proportion of NK cells was four 
times higher in the D-LN of mice infected with ECTV     166 
as compared with those infected with Rev166 (  Fig. 3 C  ) or 
WT (not depicted), indicating that one eff  ect of the type I 
IFN bp on innate immunity is to reduce the recruitment of 
NK cells to the D-LN. However, the type I IFN bp must also 
aff  ect components of innate immunity other than NK cells 
(e.g., macrophages and/or polymorphonuclear cells), because 
RAG-1  –  defi  cient mice depleted of NK cells with anti-Asialo 
GM1 antibody and infected with ECTV     166 succumbed to 
mousepox later than those infected with Rev166 (  Fig. 3 D  ). 
  The ECTV type I IFN bp binds to mouse IFN-     tightly, blocks 
its biological function in tissue culture, and complements 
    166 in vivo 
  To further study the role of the type I IFN bp in ECTV 
pathogenesis and immunity, we cloned and produced in 
  Escherichia coli   a Rec His-tagged ECTV type I IFN bp, which 
was recovered from inclusion bodies, purifi  ed by Ni  2+   affi   n-
ity chromatography, and refolded as previously described for 
the ECTV EVM135 protein (  64  ). Because the OPV type I 
IFN bp is predicted to be glycosylated (which potentially 
could aff  ect its binding to IFN-    ), we also produced and pu-
rifi  ed His-tagged ECTV and VACV type I IFN bp using a 
baculovirus system, as previously published (  66  ). Irrespective 
of the viral origin or method of production, all Rec proteins 
bound to mouse IFN-     with very similar kinetics, as deter-
mined by surface plasmon resonance (SPR), and were char-
acterized by a very slow K  off     (indicating a very tight binding) 
and a high affi   nity (  Fig. 4 A  ).   The mean K  d   values for two in-
dependent experiments for the ECTV protein expressed in 
  E. coli   and the VACV protein expressed in the baculovirus 
system were 25.1 and 17.1, with       2   values of 0.8 and 0.9, re-
spectively. We were unable to fi  t the binding data for the 
ECTV protein expressed in the baculovirus system to the 1:1 
Langmuir binding model. This was caused by the very slow 
off   rates, particularly at the lower concentrations of IFN-     
(  Fig. 4 A  , right). However, a partial fi  t for the K  off     and K  on   on 
this interaction was obtained for each of the two highest con-
centrations of IFN-    . In each case, the calculated K  d   was in 
the nanomolar range or below, indicating that the interaction 
of the ECTV protein produced in the baculovirus system was 
similar in its dissociation constant to the interaction of IFN-     
with the ECTV protein expressed in   E. coli  . Importantly, the 
K  d   values that we obtained were consistent with those re-
ported by Symons et al. for the binding of the VACV protein 
to mouse type I IFNs, which was     10-fold lower than the 
binding of the VACV protein to human type I IFNs (  45  ). 
Overall, the SPR experiments indicate that the VACV and 
ECTV type I IFN bp are similar in their ability to bind to 
mouse IFN-    . Because the protein produced in   E. coli   bound 
with similar kinetics as the proteins produced in the baculo-
virus system, the data also indicate that glycosylation of the 
    Table I.        Lethality of different ECTV isolates 
Experiment Virus Dose (PFU) Dead/total
1 Rev166 0.1 2/6
1 3/6
300 5/5
WT 0.1 2/6
1 4/4
10 4/4
300 5/5
    166 300 0/5
10  6 0/5
10  7 0/4
5   ×   10  7 0/3
2 Rev166 0.1 1/6
1 2/6
WT 1 6/6
    166 5   ×   10  7 0/4
3 Rev166 0.2 2/6
2 6/6
WT 0.2 5/6
    166 5   ×   10  7 0/4
189898-p7.5-EGFP 0.5 2/6
5 6/6
Mice were infected with the indicated viruses serially diluted in PBS from stocks. For 
experiments 1 and 2, the dose was calculated according to the virus titer determined in 
the virus stock. For experiment 3, fi  nal dilutions were retitered. Based on the results, we 
estimate LD  50   values for the different viruses as follows: Rev166,   <  2; WT,   <  0.2; p7.5-
EGFP,   <  5;    166,   > 5   ×   10 7  . These experiments are independent of those in   Fig. 2 C  .986 ECTROMELIA VIRUS TYPE I IFN BINDING PROTEIN IN VIRULENCE AND AS A VACCINE | Xu et al.
capable of blocking the function of IRMs essential for virus 
virulence could contribute to protective immunity. To elu-
cidate whether the type I IFN bp is a natural target of the 
antibody response, we used Rec type I IFN bp as antigen in 
ELISA to demonstrate that B6 mice that recovered from in-
fection with Rev166 but not with     166 had high titer anti-
bodies to type I IFN bp (  Fig. 5 B  , compare open squares with 
closed triangles), indicating that the type I IFN bp is a natural 
target of anti-ECTV immunity. Sera from BALB/c mice that 
had been infected with VACV also reacted with Rec type I 
IFN bp (  Fig. 5 B  , closed circles), demonstrating that VACV 
infection induces antibodies to the VACV homologue (B19R) 
and that antibodies to the two proteins are cross-reactive. Even 
more important, sera from mice that recovered from Rev166 
but not from     166 infection had the capacity to block the bio-
logical activity of Rec type I IFN bp in tissue culture (  Fig. 5 C  ), 
suggesting that antibodies to the type I IFN bp may have 
protective eff  ects in vivo. 
  Immunization with Rec ECTV type I IFN bp prevents 
lethal mousepox 
  Given that the type I IFN bp is essential for ECTV virulence 
in BALB/c mice and that antibodies can neutralize its bio-
logical eff  ect in vitro, we tested whether immunization with 
Rec type I IFN bp induced a protective immune response. 
Sera from BALB/c mice immunized three times with Rec 
type I IFN bp had high antibody titers to ECTV type I IFN 
bp (  Fig. 5 D  ), and also neutralized the biological activity of 
Rec type I IFN bp but not ECTV infectivity in tissue culture 
(not depicted). Strikingly, all BALB/c mice immunized with 
Rec type I IFN bp and challenged with 300 PFU ECTV WT 
survived the infection with minimal weight loss (    10%), 
whereas all mice immunized with control Rec human Her2/
  neu   died (  Fig. 5 E  ). Thus, anti  –  type I IFN bp antibodies pro-
tect from mousepox, and Rec type I IFN bp can be successfully 
used as a vaccine to prevent it. 
    DISCUSSION   
  Three major conclusions can be drawn from the data de-
scribed in this paper: (a) the type I IFN bp is essential for 
ECTV virulence, (b) the type I IFN bp is a natural target of 
the anti-OPV immune response, and (c) the type I IFN bp is 
an eff  ective target to immunize against mousepox. 
  In regard to the role of the type I IFN bp in virulence, it 
is interesting to note that VACV lacking the type I IFN bp 
was found to be attenuated     100-fold in mice infected 
through the intranasal route (  45  ). This attenuation, however, 
was modest when compared with the   >  10  7  -fold attenuation 
of ECTV     166 inoculated via the footpad, as reported in this 
paper. This diff  erence is surprising given that the VACV and 
ECTV proteins bind mouse IFN-     with similar affi   nities and 
that both fail to block the biological activity of mouse IFN-     
(  Fig. 4  ) (  44  ). Whatever the reason, our demonstration that 
    166 is extremely attenuated further stresses the need to ex-
plore the role of virulence factors in animal species that have 
a natural susceptibility to the virus in question. The fi  nding 
    Figure 3.         ECTV type I IFN bp affects adaptive and innate immunity.   
(A) Mice were infected with the indicated viruses. 5 d PI, anti-ECTV CD8  +  
T cell responses were determined in the popliteal D-LN. Plots are gated on 
CD8  +   cells. Data correspond to a pool of three lymph nodes and are repre-
sentative of three similar experiments. Axes are log10 of fl  uorescence inten-
sity. Percentages of cells are shown. (B) RAG-1  –  defi  cient mice were infected 
with the indicated viruses and observed for survival. Data correspond to fi  ve 
mice per group. (C) BALB/c mice were infected with the indicated viruses. 
3 d PI, cells from the D-LN and contralateral non  –  DLN (ND-LN) were stained 
as indicated. Data correspond to a pool of three lymph nodes and are repre-
sentative of two experiments. Axes are log10 of fl  uorescence intensity. Per-
centages of cells are shown. (D) RAG-1  –  defi  cient mice depleted of NK cells 
using anti-Asialo GM1 antibody were infected with the indicated viruses 
and observed for survival. Data correspond to fi  ve mice per group.    JEM VOL. 205, April 14, 2008 
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intriguing. Several possibilities could explain this conundrum, 
all of them enticing. One possibility is that besides IFN-     
binding, the ECTV type I IFN bp protein has a second func-
tion that is essential for virulence. This second function, how-
ever, would also have to be performed in the extracellular 
environment, because inoculation of the Rec protein rescued 
virulence of     166 and antibodies to the type I IFN bp in-
duced by immunization prevented mousepox after infection 
with WT ECTV. However, our fi  nding that infection with 
    166 is lethal to IFNAR1-defi  cient mice strongly argues that 
it is the IFN-     binding function of the type I IFN bp that is 
essential for virulence. Another possibility is that IFN-     is not 
produced or produced in insuffi   cient quantities during ECTV 
infection. This possibility seems unlikely because IFN-      –  de-
fi  cient mice were found to be very sensitive to intranasal 
VACV infection (  39  ). Finally it is also possible that the in vivo 
antiviral functions of IFN-     and -     are nonoverlapping. 
  The attenuation of     166 was accompanied by a major 
increase in the magnitude of the innate and adaptive immune 
responses in the D-LN, revealing the important role of the 
type I IFN bp in modifying the anti-ECTV immune re-
sponse. This increased immunogenicity may be the result of 
increased IFN-     signaling to immune cells in the absence of 
that deletion of only one protein that is nonessential for virus 
replication results in a virus that is attenuated   >  10  7  -fold 
is very surprising and indicative of the important role of the 
type I IFN bp in ECTV virulence. A remaining question is 
whether the type I IFN bp is unique among IRMs and is the 
only Achilles  ’   heel of ECTV virulence, or whether other 
IRMs will also have such an essential role. This question can 
be answered by testing other ECTV IRMs. In this regard, it 
has recently been shown that ECTV lacking the IFN-     bp 
(EVM158) is only mildly attenuated because it spread sub-
stantially in vivo, and because it induced mousepox and some 
deaths in susceptible BALB/c mice even at doses of 500 PFU 
(  50  ). Another important question is whether the type I IFN 
bp, which is conserved among most OPVs, is also essential for 
the virulence of other OPVs in their natural hosts or whether 
diff  erent IRMs will be essential for each virus  –  host interaction. 
This question will be more diffi   cult to address, as it requires 
matching viruses with natural hosts. 
  IFN-     and -     are known to use the same signaling path-
way to induce the antiviral state in cells (  29  ). Because the type I 
IFN bp inactivates mouse IFN-     but not -    , and because no 
other IFN-     blocking activity was detected in supernatants of 
ECTV-infected cells (  44  ), the extreme attenuation of     166 is 
    Figure 4.         ECTV type I IFN bp binds to mouse IFN-     with high affi  nity, blocks its biological activity in tissue culture, and complements 
    166 in vivo.   (A) SPR sensorgrams for the interaction of mouse IFN-     3 with the indicated Rec type I IFN bp. Values on the y axes are arbitrary response 
units. Continuous lines correspond to the experimental values after subtracting the control sensorgram; dashed lines correspond to the data fi  tted to a 
1:1 Langmuir binding model. The graph corresponding to the ECTV protein produced in the baculovirus system (right) does not have dashed lines because 
the data could not be fi  tted to the 1:1 Langmuir model due to a slow K  off  . Data are representative of two identical experiments. (B) MEFs were incubated 
with the indicated amounts of IFN-     or  -    for 24 h in the presence or absence of the indicated amounts of Rec ECTV type I IFN bp, followed by infection 
with VSV. After an additional 24-h incubation, the cells were fi  xed and stained with crystal violet. Data are representative of two identical experiments. 
(C) Mice were inoculated i.v. with 50   μ  g of Rec ECTV type I IFN bp immediately, and 3 d PI with ECTV     166. A group of control-infected mice received PBS 
instead of Rec ECTV type I IFN bp, whereas a second control group received Rec ECTV type I IFN bp but remained uninfected. Survival was monitored. Data 
are representative of three experiments.     988 ECTROMELIA VIRUS TYPE I IFN BINDING PROTEIN IN VIRULENCE AND AS A VACCINE | Xu et al.
and other IRMs may substantially contribute to the protec-
tive eff  ects induced by live VACV vaccination, and may be 
one of the reasons why immunization with killed virions is 
not very eff  ective at inducing protection (  77  ). 
  Vaccines against pathogen-secreted proteins are in use for 
bacterial diseases (e.g., tetanus and anthrax). However, the use 
of secreted virulence factors as vaccines to prevent viral dis-
eases is unheard of. Thus, our work provides the framework 
for a novel approach to antiviral vaccination using nonstruc-
tural virulence factors as targets. Interestingly, over three de-
cades ago it was reported that a soluble early antigen expressed 
by VACV-infected cells could be used to induce skin resis-
tance to VACV in rabbits (  78  ). Remarkably, this soluble anti-
gen was later found to contain the type I IFN bp (  79, 80  ). Its 
possible use as a vaccine, however, was never explored further. 
It could be argued that such an approach may not be useful 
type I IFN bp. Alternatively, the presence of fully active IFN-     
during infection with     166 may directly aff  ect the level of 
virus replication, and this may determine the level of activation 
of the various arms of the immune system. 
  Because of the risks of emerging OPV infections and OPV 
weaponization, and because the VACV-based vaccine is not 
safe by current standards, there is a considerable interest in 
developing novel anti-OPV vaccines (  64, 69  –  76  ). In this 
context, our fi  nding that the type I IFN bp is a natural target 
of the antibody response indicates that deletion of IRMs from 
live vaccines may be a double-edged sword. On one hand, it 
may increase the safety of the vaccine. On the other hand, it 
is also possible that these deletions will decrease vaccine effi   -
cacy because, as we now know, the type I IFN bp of OPVs 
is a natural target of the antibody response and is cross-reac-
tive. Thus, it is very possible that antibodies to type I IFN bp 
    Figure 5.         The OPV type I IFN bp is a natural target of the antibody response and can be used as an effective vaccine.   (A) Sera from mice in-
fected with the indicated viruses were tested for anti-ECTV antibodies in ELISA using purifi  ed virus particles as antigen bound to the plate. (B) As in A, but 
using Rec ECTV type I IFN bp as antigen. (C) MEFs were treated for 24 h with 20 IU IFN-     in the presence or absence of the indicated amounts of Rec 
ECTV type I IFN bp and/or sera from ECTV     166 or Rev166 immune mice. MEFs were next infected with VSV, incubated for 24 h, and fi  xed and stained 
with crystal violet. (D) BALB/c mice were immunized and boosted twice with Rec ECTV type I IFN bp or control Rec human HER2/  neu   produced in   E. coli . 
As additional controls, BALB/c mice were infected with     166, and B6 mice were infected with Rev166. 3 wk after the last boost or infection, sera was 
collected and anti-ECTV type I IFN bp was determined by ELISA. (E) The immunized mice in D were challenged with 300 PFU of WT ECTV and survival was 
monitored. Data correspond to fi  ve mice per group and are representative of three identical experiments.     JEM VOL. 205, April 14, 2008 
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later, green fl  uorescent plaques (Fig. S1 C) were picked with a pipette tip and 
used to infect a new set of cells. The purifi  cation procedure was iterated fi  ve 
times until all plaques were fl  uorescent. The viral DNA from     300 base pair 
downstream and upstream of EVM166 was amplifi  ed by PCR, cloned, and 
sequenced. An isolate with the correct sequence was expanded for subsequent 
experiments with the same methods as for WT virus. To generate Rev166 
(Fig. S1 B), a procedure similar to that for     166 was used, but the targeting 
vector contained the entire coding sequence of EVM166 and the target virus 
was     166. Nonfl  uorescent plaques were amplifi  ed (Fig. S1 C). 
  Infections and immunizations.     For mouse infections with ECTV, mice 
were inoculated with 300 PFU of the various ECTV in the left hind footpad 
in 50   μ  l PBS. It should be noted that in the past (  64  ), we have used BALB/c 
mice from the FCCC stock in which 20  –  40% survival was frequently ob-
served with 3,000 PFU ECTV WT, whereas the LD  50   that we recently de-
termined for BALB/c mice from NCI (as well as from the Jackson Laboratory) 
is   <  5 PFU, and 5 PFU is 100% lethal. The reason for this diff  erence in sus-
ceptibility to lethal mousepox in BALB/c mice from diff  erent origins is un-
known. Mice were monitored for signs of mousepox and death, and VACV 
infection was performed as previously described (  55, 56, 63, 64  ). For NK cell 
depletions, mice were inoculated intraperitoneally with 10   μ  l of anti-Asialo 
GM1 antibody (Wako Pure Chemical Industries, Ltd.) 1 d before viral infec-
tion. For immunizations, male BALB/c mice were immunized every other 
week, three times with 20   μ  g of Rec type I IFN bp or Rec human HER2/
  neu   emulsifi  ed in IFA. 3 wk after the last immunization, the mice were bled 
to determine antibody in serum and were infected with WT ECTV 2 d later. 
For VACV immunizations, mice were infected IP with 5   ×   10  6   PFU. 
  Flow cytometry.     Flow cytometry was performed as previously described 
(  55, 56, 59, 63, 64  ). 
  Production and use of Rec proteins.     The coding sequence for the 
ECTV type I IFN bp without the signal peptide (residues 1  –  31) was ampli-
fi  ed by PCR from viral DNA and inserted into vector pET28 (Novagen) 
with a C-terminal His tag. Expression and refolding of Rec ECTV type I 
IFN bp was as previously described for EVM135 (  64  ), except that the re-
moval of urea was performed by serial dialysis overnight against 6, 4, 2, 1, 
and, fi  nally, 0 M urea at room temperature. The full-length, His-tagged 
ECTV and VACV type I IFN bp  ’  s were expressed in a baculovirus system 
and purifi  ed by Ni  2+   affi   nity chromatography, as previously described for 
other VACV proteins (  66  ). 
  ELISA.     To determine antibodies to ECTV type I IFN bp in sera from in-
fected or immunized mice, 96-well fl  at-bottom radio immunoassay/enzyme 
immunoassay plates (Corning) were coated with 100 ng of Rec ECTV type I 
IFN bp or 1,000 PFU of sucrose-purifi  ed ECTV in 0.1 ml PBS at 4  °  C 
overnight. Plates were blocked for 2 h at 37  °  C with PBS containing 1% 
BSA. Mice sera were serially diluted in PBS containing 0.5% BSA and 0.05% 
Tween 20, and 0.1 ml was added to each well. The plates were incubated for 
1 h at 37  °  C and washed three times with PBST (PBS with 0.05% Tween 
20). 0.1 ml of peroxidase-conjugated affi   nity-purifi  ed goat anti  –  mouse IgG 
(     chain specifi  c; KPL) was added to each well diluted 1:2,000 in PBST, in-
cubated for 0.5 h at 37  °  C, and washed fi  ve times with PBST. 50   μ  l of Sure-
Blue TMB 1-Component Microwell Peroxidase Substrate (KPL) was added 
to each well, and the reaction was stopped by the addition of 0.1 ml of 0.12 M 
HCl. The OD at 450 nm was determined using a microplate spectropho-
tometer (    Quant; Bio-Tec). 
  VSV inhibition assays.     To determine the biological activity of Rec ECTV 
type I IFN bp in vitro, confl  uent MEFs or L929 cells in 24-well plates were 
treated with either 200   μ  l of supernatants (passed through a 0.1-  μ  M pore fi  lter) 
from BSC-1 cells infected for 5 d with the indicated ECTV (1 PFU/cell), or 
with the amounts of Rec ECTV type I IFN bp indicated in the fi  gures. The 
cells were incubated for 2 h at 37  °  C in 0.5 ml DMEM with 10% FBS, followed 
by the addition of the amounts of mouse IFN-     3 or -     (PBL Interferon 
because it prevents disease but does not provide sterilizing im-
munity, thus maintaining the possibility of virus spread. This 
argument can be contested because one of the biggest suc-
cesses in medical history, VACV immunization, does not pro-
vide sterilizing immunity either to humans or mice (  1, 56  ). In 
the case of subunit vaccines against OPVs, all approaches thus 
far have focused on structural proteins, with some success (  64, 
69  –  71, 73  ). Given the strong protection induced by Rec type I 
IFN bp, we now propose that combining essential IRMs and 
structural proteins in new vaccine formulations may be the 
best approach for an eff  ective and safe subunit vaccine to OPVs 
and, possibly, other viruses. In addition, our experiments open 
the possibility that the type I IFN bp of OPVs could be used 
as a pharmacological target to prevent disease in individuals 
exposed or at risk of exposure to pathogenic OPVs. 
  MATERIALS AND METHODS 
  Mice.     BALB/c mice were purchased from the National Cancer Institute 
(NCI). RAG1-defi  cient mice on a B6 background were originally purchased 
from the Jackson Laboratory and bred at FCCC. B6 mice were obtained 
from the FCCC colony. IFNAR1-defi  cient mice in a 129S2/SvPas back-
ground, as previously described (  81  ), were bred at FCCC from breeders ob-
tained from R. Schreiber (Washington University Medical School, St. Louis, 
MO). Control 129S2/SvPas mice were purchased from Charles River Labo-
ratories. All mice were used in experiments when they were 5  –  12 wk old. All 
protocols involving mice were approved by the FCCC Institutional Animal 
Care and Use Committee. 
  Media and cells.     Media and cells were as previously described (  55, 56, 63, 
64  ), except for mouse embryonic fi  broblasts (MEFs) that were prepared ac-
cording to standard methods (  82  ) from day 12  –  14 embryos and maintained 
in DMEM containing 15% FBS and antibiotics. 
  Viruses.     Stocks of WT VACV Western Reserve strain were produced in tis-
sue culture, as previously described (  55, 56, 63, 64  ). Stocks of ECTV were 
produced in A9 cells (American Type Culture Collection). When indicated in 
the fi  gures, ECTV was purifi  ed over a 36% sucrose cushion, as previously de-
scribed (  83  ), but from spleen and liver homogenates from infected BALB/c 
mice (7 d PI) instead of cell lysates. For ECTV multistep growth curves, 
BS-C-1 or A9 cells were infected with ECTV at an multiplicity of infection 
of 0.01 for 1 h. Unabsorbed virus was removed by washing the cells with PBS 
three times, and the cells were incubated at 37  °  C/5% CO  2   in 3 ml DMEM 
containing 2.5% FBS. At various times PI, supernatants and cells were har-
vested separately and virus titers were determined. All growth analyses were 
performed in triplicate. VACV and ECTV titers in stocks, tissues, and cells 
were as previously described (  55, 56, 63, 64  ). VSV Indiana strain (provided by 
J.T. Guo, Drexel Institute for Biotechnology and Virology Research, 
Doylestown, PA) was expanded in A9 cells, and the viral yield was determined 
by a plaque assay on Vero cells. ECTV 189898-p7.5-EGFP was previously 
described (  59  ). To generate ECTV     166, we used an adaptation of the method 
of homologous recombination (model in Fig. S1 A) (  26, 59  ). Briefl  y, a target-
ing vector was made with the 5     300 base pair of ECTV EVM166 correspond-
ing to nucleotides 187856  –  188155 of the ECTV Moscow genome (  13  ), the 
early/late OPV 7.5 promoter, the complete sequence of EGFP, and the 3     300 
base pair of EVM166 corresponding to nucleotides 188633  –  188932 of the 
ECTV Moscow genome, in that order, were inserted into plasmid (Bluescript 
II SK+; Stratagene). This targeting vector was used to transfect mouse A9 cells 
using Lipofectamine 2000, according to the manufacturer  ’  s instructions (Invit-
rogen). The transfected cells were infected with 0.3 PFU/cell of WT ECTV 
Moscow strain in sixwell plates. 2 d later, transfected/infected A9 cells were 
harvested using a rubber policeman, frozen, and thawed, and diff  erent dilu-
tions of cell lysates were used to infect BSC-1 cells in sixwell plates. 2 h after 
infection, the cells were overlaid with media containing 0.5% agarose. 4 d 990 ECTROMELIA VIRUS TYPE I IFN BINDING PROTEIN IN VIRULENCE AND AS A VACCINE | Xu et al.
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Source) indicated in the fi  gures. After overnight incubation, the cells were in-
fected with the indicated PFU of VSV in 0.5 ml DMEM with 2.5% FBS. After 
1 h of incubation, the media was replaced with 1 ml of complete DMEM with 
10% FBS, and the cells were incubated overnight. The cells were washed 
twice with PBS, and the monolayer was visualized by fi  xing with methanol 
and staining with 1% crystal violet. To determine neutralization of the biologi-
cal activity of Rec ECTV type I IFN bp with immune sera, the VSV inhibi-
tion assay was performed in the presence of the indicated amounts (as shown 
in the fi  gures) of heat-inactivated (56  °  C for 30 min) sera from infected (3 wk 
PI) or Rec ECTV type I IFN bp  –  immunized mice in 0.5 ml DMEM with 
10% FBS 1 h before the addition of Rec ECTV type I IFN bp. 
  In vivo complementation of     166.     To determine the biological activity 
of Rec ECTV type I IFN bp in vivo, mice were inoculated i.v. with 50   μ  g 
of Rec IFN-     bp in 0.5 ml PBS immediately, and 3 d PI with ECTV     166. 
A group of control infected mice received PBS instead of Rec ECTV type I 
IFN bp, whereas a second control group received Rec ECTV type I IFN bp 
but remained uninfected. Mousepox and death were determined as previ-
ously described (  55, 56, 63, 64  ). 
  SPR.     Experiments were performed on an optical biosensor (BIACORE 
3000; GE Healthcare) at 25  °  C. The running buff  er for the experiments was 
HBS-EP (10 mM Hepes, 150 mM NaCl, 3 mM EDTA, 0.005% polysorbate 
20). Approximately 2,000 response units of purifi  ed Rec proteins were cou-
pled to fl  ow cells (Fc) 2  –  4 of a CM5 sensor chip via primary amines, accord-
ing to the manufacturer  ’  s specifi   cations. Fc1 was activated and blocked 
without the addition of protein. To characterize the binding of IFN-     3 to 
the proteins, the fl  ow path was set to include all fl  ow cells, the fl  ow rate was 
50   μ  l/min, and the data collection rate was set to high. Protein samples were 
serially diluted in HBS-EP. Binding of each IFN-     concentration was al-
lowed to occur for 2 min, with the wash delay set for an additional 2 min to 
allow for a smooth dissociation curve. The chip surface was regenerated by 
injecting brief pulses of buff  er containing 1 M NaCL and 0.2 M sodium car-
bonate, pH 11.5, until the response signal returned to baseline. SPR data were 
analyzed with BIAevaluation software (version 3.0; GE Healthcare), which 
employs global fi  tting. Sensorgrams were corrected for nonspecifi  c binding by 
subtracting the control sensorgram (Fc1) from the experimental sensorgrams. 
Model curve fi  tting was done with a 1:1 Langmuir binding model. This is the 
simplest model for the interaction between receptor and ligand, as it follows 
the equation A + B   →   AB. The rate of association (K  on  ) is measured from the 
forward reaction, whereas K  off     is measured from the reverse reaction. 
  Statistics.     Data were analyzed using Excel software (Analysis Tool Pack; 
Microsoft). 
  Online supplemental material.    Fig. S1 shows models for the strategies used 
to generate     166 (A) and Rev166 (B), and examples of fl  uorescent (    166) 
and nonfl  uorescent (WT) ECTV plaques (C). Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20071854/DC1. 
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